521 AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies

Tingting Zhong(Guangzhou Development Zone Hospital), Min Jing, Xinrong He(Sun Yat-sen University), Baiyong Li(China National Pharmaceutical Group Corporation (China)), Xinghua Pang, Yu Xia(Wenzhou Medical University), Zhaoliang Huang, Chunshan Jin
Regular and Young Investigator Award Abstracts
November 1, 2022
Cited by 18


Related Papers